癌症免疫療法藥物研發發現外包市場規模、佔有率、趨勢分析報告：按藥物類型、癌症類型、服務類型、地區和細分市場預測，2023-2030 年

癌症免疫治療藥物研發外包市場成長與趨勢：

Grand View Research, Inc. 的最新報告顯示，到2030年，全球癌症免疫療法藥物研發發現外包市場預計將達到 25 億美元。

預計2023年至2030年該市場將以9.8%的年複合成長率擴張。該市場的主要促進因素是全球癌症患病不斷上升，製藥和生物技術公司對癌症研究的投資增加以及人們對先進癌症治療的認知不斷提高。

在 COVID-19 大流行的早期階段，癌症免疫療法藥物研發市場的成長陷入停滯。這是由於感染了 COVID-19 的患者大量湧入，需要緊急加護治療和治療。此外，供應鏈中斷、防止疫情的旅行限制以及嚴格的法規減緩癌症免疫治療藥物研發市場的發展。然而，製藥公司和法規的策略方法可以顯著減少這種影響。

市場的其他促進因素包括外包藥物研發發現的需求迅速成長，因為與內部研發成本相比，外包藥物發現的成本較低，並且可以提供多種好處的稅額扣抵。例如，稅務機關常見的問題將減少，製藥和生物技術公司將能夠利用 CRO 有效規劃其全球專案。世界各國政府也積極參與並採取措施癌症治療。例如，2022年4月，印度政府推出了17家癌症治療醫院。這是塔塔信託公司和政府之間的一項聯合計劃，目的是創建一個負擔得起的癌症治療網路。

此外，多種新分子和新的免疫治療方案開發用於癌症免疫治療，包括檢查點抑制劑、免疫調節劑、腫瘤浸潤淋巴細胞和CAR-T細胞治療。其他幾種藥物仍在研發中，以確認抗癌功效。

癌症免疫療法藥物研發外包市場報告亮點

• 單株抗體領域佔市場主導地位，2022年佔最大銷售佔有率，達63.0%。這種成長得益於高功效和不斷增加的法規核准。
• 鉛篩選和表徵領域預計在預測期內將以最快的年複合成長率成長。這是由於越來越多的新的有效方法減少了該領域有效檢測所需的時間。
• 2022年，肺癌細分市場佔收益佔有率最大，達 24.5%。這種增加是由於針對這種癌症類型的許多有效免疫療法的普及。
• 北美市場佔據主導地位，2022年佔 36.2%的銷售佔有率。這是由於該地區對新技術的需求不斷成長以及癌症罹患率不斷上升。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 癌症免疫治療藥物研發外包市場變數、趨勢和範圍

• 市場體系預測
  • 母市場預測
  • 相關/附隨市場預測
• 普及和成長預測圖
• 市場動態
  • 市場促進因素分析
  • 市場抑制因素分析
• 癌症免疫療法藥物研發外包市場分析工具
  • 產業分析-波特五力分析
  • PESTEL分析

第4章 癌症免疫治療藥物研發外包：藥物類型的估計和趨勢分析

• 癌症免疫治療藥物研發外包市場：重點
• 癌症免疫療法藥物研發外包市場：2022年和2030年趨勢和市場佔有率分析
• 單株抗體
• 免疫調節劑
• 癌症疫苗和溶瘤病毒療法
• 其他

第5章 癌症免疫治療藥物研發外包：服務類型估算與趨勢分析

• 癌症免疫治療藥物研發外包市場：重點
• 癌症免疫療法藥物研發外包市場：2022年和2030年趨勢和市場佔有率分析
• 目標識別與檢驗
• 鉛篩選與表徵
• 基於細胞的檢測

第6章 癌症免疫治療的藥物研發外包：癌症類型的估計和趨勢分析

• 癌症免疫治療藥物研發外包市場：重點
• 癌症免疫療法藥物研發外包市場：2022年和2030年趨勢和市場佔有率分析
• 肺
• 胸部
• 大腸直腸
• 黑色素瘤
• 攝護腺
• 頭部和頸部
• 卵巢
• 胰臟

第7章 癌症免疫治療藥物研發外包市場：區域估計和趨勢分析

• 區域展望
• 依地區分類的癌症免疫療法藥物研發外包市場：要點
• 北美洲
• 歐洲
• 亞太地區
• 拉丁美洲
• 中東、非洲

第8章 競爭形勢

• 主要市場參與企業的最新趨勢和影響分析
• 市場參與企業分類
  • Explicyte Immuno-Oncology
  • Aquila Biomedical
  • Horizon Discovery Group plc
  • Crown Bioscience Inc.
  • Promega Corporation
  • HD Co. Ltd.
  • BPS Biosciences Inc.
  • Gen script Biotech Corporation
  • Celentyx Ltd.
  • ImmuneXperts SA
  • Personalis
  • STC Biologics
  • Molecular Imaging Inc. (MI Bioresearch Inc.)
  • Covance, Inc.

Cancer Immunotherapy Drug Discovery Outsourcing Market Growth & Trends:

The global cancer immunotherapy drug discovery outsourcing market size is expected to reach USD 2.5 billion by 2030, according to a new report by Grand View Research, Inc.. The market is expected to expand at a CAGR of 9.8% from 2023 to 2030. The main drivers of this market are the increasing prevalence of cancer Worldwide, increasing investment by pharmaceutical and biotechnology companies in cancer research, and the rise in awareness among people for advanced treatment of cancer.

In the early stages of the COVID-19 pandemic, there was a halt in the growth of the cancer immunotherapy drug discovery market. This decrease in cancer immunotherapy drug discovery is due to the influx of a large number of patients that are infected with COVID-19 and require immediate intensive care and treatment. Also, disruptions in the supply chain, travel restrictions to prevent pandemics, and strict regulations have resulted in delays in the cancer immunotherapy drug discovery market. However, this impact will be significantly reduced by adopting strategic methods taken by pharmaceutical companies and regulatory authorities.

Other drivers of the market are the rising demand for outsourcing of drug discovery, which is increasing rapidly due to low cost as compared to in-house R&D costs, and the use of a tax credit that allows several benefits. For instance, reduces problems that are generally encountered with taxation authorities and it allows pharmaceutical and biotechnology companies to plan effectively their global projects with CRO. Also, the governments are actively participating and taking initiatives for cancer treatment. For instance, in April 2022, the government of India launched 17 hospitals for the treatment of cancer. This is a joint initiative taken by Tata trust and the government, to create an affordable cancer care network.

Also, there is the development of various new molecules for cancer immunotherapy and new immunotherapeutic options such as checkpoint inhibitors, immunomodulators, tumor-infiltrating lymphocytes, and CAR-T cell therapy. Several others are still in the pipeline to check their efficacy against cancer.

Cancer Immunotherapy Drug Discovery Outsourcing Market Report Highlights:

• The monoclonal antibodies segment dominated the market and accounted for the largest revenue share of 63.0% in 2022. This growth is due to high efficacy and a rise in regulatory approvals
• The lead screening and characterization segment is expected to grow at the fastest CAGR during the forecast period. This is due to a rise in new and effective ways to decrease the time for effective assays in this segment
• The lung cancer segment accounted for the largest revenue share of 24.5% in 2022. This rise is due to the large number of prevalent effective immunotherapies for this cancer type
• North America dominated the market and accounted for a revenue share of 36.2% in 2022. This is due to a rise in demand for new technologies and an increasing incidence of cancer in the region

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Service type
  • 1.1.2. Cancer type
  • 1.1.3. Drug type
  • 1.1.4. Regional scope
  • 1.1.5. Estimates and forecast timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Model Details
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Service type outlook
  • 2.2.2. Cancer type outlook
  • 2.2.3. Drug type outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Cancer Immunotherapy Drug Discovery Outsourcing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
  • 3.3.2. Market restraint analysis
• 3.4. Cancer Immunotherapy Drug Discovery Outsourcing Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Cancer Immunotherapy Drug Discovery Outsourcing: Drug Type Estimates & Trend Analysis

• 4.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 4.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 4.3. Monoclonal Antibodies
  • 4.3.1. Monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.4. Immunomodulators
  • 4.4.1. Immunomodulators market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. Cancer Vaccines and Oncolytic Viral Therapy
  • 4.5.1. Cancer vaccines and oncolytic viral therapy market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. Others
  • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Cancer Immunotherapy Drug Discovery Outsourcing: Service Type Estimates & Trend Analysis

• 5.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 5.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 5.3. Target Identification and Validation
  • 5.3.1. Target identification and validation market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.4. Lead Screening and Characterization
  • 5.4.1. Lead screening and characterization market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Cell-based Assays
  • 5.5.1. Cell-based assays market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Cancer Immunotherapy Drug Discovery Outsourcing: Cancer Type Estimates & Trend Analysis

• 6.1. Cancer Immunotherapy Drug Discovery Outsourcing Market: Key Takeaways
• 6.2. Cancer Immunotherapy Drug Discovery Outsourcing Market: Movement & Market Share Analysis, 2022 & 2030
• 6.3. Lung
  • 6.3.1. Lung market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.4. Breast
  • 6.4.1. Breast market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.5. Colorectal
  • 6.5.1. Colorectal market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Melanoma
  • 6.6.1. Melanoma market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.7. Prostate
  • 6.7.1. Prostate market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.8. Head & Neck
  • 6.8.1. Head & Neck market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.9. Ovarian
  • 6.9.1. Ovarian market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.10. Pancreatic
  • 6.10.1. Pancreatic market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Cancer Immunotherapy Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Outlook
• 7.2. Cancer Immunotherapy Drug Discovery Outsourcing Market by Region: Key Takeaway
• 7.3. North America
  • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.3. France
    • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.6. Sweden
    • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.7. Norway
    • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.2. China
    • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.3. India
    • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.5. Thailand
    • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.5.6. South Korea
    • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. Mexico
    • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
• 7.7. MEA
  • 7.7.1. Saudi Arabia
    • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Market Participant Categorization
  • 8.2.1. Explicyte Immuno-Oncology
    • 8.2.1.1. Company overview
    • 8.2.1.2. Financial performance
    • 8.2.1.3. Product benchmarking
    • 8.2.1.4. Strategic initiatives
  • 8.2.2. Aquila Biomedical
    • 8.2.2.1. Company overview
    • 8.2.2.2. Financial performance
    • 8.2.2.3. Product benchmarking
    • 8.2.2.4. Strategic initiatives
  • 8.2.3. Horizon Discovery Group plc
    • 8.2.3.1. Company overview
    • 8.2.3.2. Financial performance
    • 8.2.3.3. Product benchmarking
    • 8.2.3.4. Strategic initiatives
  • 8.2.4. Crown Bioscience Inc.
    • 8.2.4.1. Company overview
    • 8.2.4.2. Financial performance
    • 8.2.4.3. Product benchmarking
    • 8.2.4.4. Strategic initiatives
  • 8.2.5. Promega Corporation
    • 8.2.5.1. Company overview
    • 8.2.5.2. Financial performance
    • 8.2.5.3. Product benchmarking
    • 8.2.5.4. Strategic initiatives
  • 8.2.6. HD Co. Ltd.
    • 8.2.6.1. Company overview
    • 8.2.6.2. Financial performance
    • 8.2.6.3. Product benchmarking
    • 8.2.6.4. Strategic initiatives
  • 8.2.7. BPS Biosciences Inc.
    • 8.2.7.1. Company overview
    • 8.2.7.2. Financial performance
    • 8.2.7.3. Product benchmarking
    • 8.2.7.4. Strategic initiatives
  • 8.2.8. Gen script Biotech Corporation
    • 8.2.8.1. Company overview
    • 8.2.8.2. Financial performance
    • 8.2.8.3. Product benchmarking
    • 8.2.8.4. Strategic initiatives
  • 8.2.9. Celentyx Ltd.
    • 8.2.9.1. Company overview
    • 8.2.9.2. Financial performance
    • 8.2.9.3. Product benchmarking
    • 8.2.9.4. Strategic initiatives
  • 8.2.10. ImmuneXperts SA
    • 8.2.10.1. Company overview
    • 8.2.10.2. Financial performance
    • 8.2.10.3. Product benchmarking
    • 8.2.10.4. Strategic initiatives
  • 8.2.11. Personalis
    • 8.2.11.1. Company overview
    • 8.2.11.2. Financial performance
    • 8.2.11.3. Product benchmarking
    • 8.2.11.4. Strategic initiatives
  • 8.2.12. STC Biologics
    • 8.2.12.1. Company overview
    • 8.2.12.2. Financial performance
    • 8.2.12.3. Product benchmarking
    • 8.2.12.4. Strategic initiatives
  • 8.2.13. Molecular Imaging Inc. (MI Bioresearch Inc.)
    • 8.2.13.1. Company overview
    • 8.2.13.2. Financial performance
    • 8.2.13.3. Product benchmarking
    • 8.2.13.4. Strategic initiatives
  • 8.2.14. Covance, Inc.
    • 8.2.14.1. Company overview
    • 8.2.14.2. Financial performance
    • 8.2.14.3. Product benchmarking
    • 8.2.14.4. Strategic initiatives

List of Tables

• Table 1 List of Abbreviations
• Table 2 North America cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 3 North America cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 4 North America cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 5 North America cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 6 U.S. cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 7 U.S. cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 8 U.S. cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 9 Canada cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 10 Canada cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 11 Canada cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 12 Europe cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 13 Europe cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 14 Europe cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 15 Europe cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 16 Germany cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 17 Germany cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 18 Germany cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 19 UK cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 20 UK cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 21 UK cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 22 France cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 23 France cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 24 France cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 25 Italy cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 26 Italy cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 27 Italy cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 28 Spain cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 29 Spain cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 30 Spain cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 31 Sweden cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 32 Sweden cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 33 Sweden cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 34 Norway cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 35 Norway cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 36 Norway cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 37 Denmark cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 38 Denmark cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 39 Denmark cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 44 China cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 45 China cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 46 China cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 47 Japan cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 48 Japan cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 49 Japan cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 50 India cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 51 India cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 52 India cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 53 Australia cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 54 Australia cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 55 Australia cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 56 Thailand cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 57 Thailand cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 58 Thailand cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 59 South Korea cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 60 South Korea cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 61 South Korea cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 62 Latin America cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 63 Latin America cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 64 Latin America cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 65 Latin America cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 66 Brazil cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 67 Brazil cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 68 Brazil cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 69 Mexico cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 70 Mexico cancer immunotherapy drug discovery outsourcing market, by material, 2018 - 2030 (USD Million)
• Table 71 Mexico cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 72 Argentina cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 73 Argentina cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 74 Argentina cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 75 Middle East and Africa cancer immunotherapy drug discovery outsourcing market, by type, 2018 - 2030 (USD Million)
• Table 76 Middle East and Africa cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 77 Middle East and Africa cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 78 Middle East and Africa cancer immunotherapy drug discovery outsourcing market, by region, 2018 - 2030 (USD Million)
• Table 79 South Africa cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 80 South Africa cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 81 South Africa cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 84 Saudi Arabia cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 85 UAE cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 86 UAE cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 87 UAE cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)
• Table 88 Kuwait cancer immunotherapy drug discovery outsourcing market, by drug type, 2018 - 2030 (USD Million)
• Table 89 Kuwait cancer immunotherapy drug discovery outsourcing market, by service type, 2018 - 2030 (USD Million)
• Table 90 Kuwait cancer immunotherapy drug discovery outsourcing market, by cancer type, 2018 - 2030 (USD Million)

List of Figure

Fig. 1 Market research process

Fig. 2 Data triangulation techniques

Fig. 3 Primary research pattern

Fig. 4 Market research approaches

Fig. 5 Value-chain-based sizing & forecasting

Fig. 6 QFD modeling for market share assessment

Fig. 7 Market formulation & validation

Fig. 8 Cancer immunotherapy drug discovery outsourcing: Market outlook

Fig. 9 Cancer immunotherapy drug discovery outsourcing: Competitive insights

Fig. 10 Parent market outlook

Fig. 11 Related/ancillary market outlook

Fig. 12 Penetration and growth prospect mapping

Fig. 13 Industry value chain analysis

Fig. 14 Cancer immunotherapy drug discovery outsourcing market driver impact

Fig. 15 Cancer immunotherapy drug discovery outsourcing market restraint impact

Fig. 16 Cancer immunotherapy drug discovery outsourcing market strategic initiatives analysis

Fig. 17 Cancer immunotherapy drug discovery outsourcing market: Drug type movement analysis

Fig. 18 Cancer immunotherapy drug discovery outsourcing market: drug type outlook and key takeaways

Fig. 19 Monoclonal antibodies market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 20 Immunomodulators market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 21 Cancer vaccines and oncolytic viral therapy market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 22 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 23 Cancer immunotherapy drug discovery outsourcing market: Service type movement analysis

Fig. 24 Cancer immunotherapy drug discovery outsourcing market: Service type outlook and key takeaways

Fig. 25 Target identification and validation market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 26 Lead screening and characterization market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 27 Cell-based assays market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 28 Cancer immunotherapy drug discovery outsourcing market: Cancer type movement analysis

Fig. 29 Cancer immunotherapy drug discovery outsourcing market: Cancer type outlook and key takeaways

Fig. 30 Lung market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 31 Breast market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 32 Colorectal market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 33 Melanoma market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 34 Prostate market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 35 Head and neck market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 36 Ovarian market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 37 Pancreatic market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 38 Global cancer immunotherapy drug discovery outsourcing market: Regional movement analysis

Fig. 39 Global cancer immunotherapy drug discovery outsourcing market: Regional outlook and key takeaways

Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 44 UK market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 46 France market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 47 Italy market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 48 Spain market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 51 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 53 Japan market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 55 India market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 56 Australia market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 57 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 58 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 59 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 60 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 61 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 62 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 63 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 64 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 65 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 66 UAE market estimates and forecasts, 2018 - 2030 (USD Million)

Fig. 67 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)